Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patientâ€™s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-14	US$0.2576	-8.21%	2,757

Real-time OTC Markets

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 11:30:40 2026-06-04 EDT			5-day change	1st Jan Change
0.4400 ^USD	+46.67%		+70.81%	-35.31%

08-07	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	849K 727K 680K 623K 1.17M 81.21M 1.18M 8.04M 3.13M 40.8M 3.19M 3.12M 135M	P/E 2024	-0.22x	P/E 2025	-0.73x
Enterprise Value	-2.01M -1.72M -1.61M -1.47M -2.76M -192M -2.8M -19M -7.41M -96.43M -7.53M -7.37M -319M	EV / Sales 2024	-	EV / Sales 2025	-491,128x
Free-Float	86.49%	Yield 2024 *	-	Yield 2025	-

08-07	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-23	Avenue Therapeutics, Inc. Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	CI
11-13	Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI
11-06	Axsome Therapeutics acquires AZD7325, a selective GABA-A modulator for treatment of epilepsy	RE
11-05	Axsome Therapeutics, Inc. entered into stock purchase agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $83.3 million.	CI
25-08-14	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-30	Avenue Therapeutics, Inc. and Annji Pharmaceutical Co., Ltd. Enters into A License Termination	CI
25-03-31	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

02-23	Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	AQ
11-06	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ
24-11-14	Avenue Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Form 8 K	PU
24-11-14	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
24-10-09	Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit	AQ

Avenue Therapeutics, Inc. Stock

Stocks

ATXI

US05360L4032

Biotechnology & Medical Research

Valuation: Avenue Therapeutics, Inc.

Chart: Avenue Therapeutics, Inc.

Latest news : Avenue Therapeutics, Inc.

Analysts' recommendations: Avenue Therapeutics, Inc.

Press Releases: Avenue Therapeutics, Inc.

News in other languages: Avenue Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avenue Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

23-04-18	MÄRKTE USA/Anleger bleiben in Deckung und warten Quartalszahlen ab
23-04-18	MÄRKTE USA/Anleger mit Blick auf Berichtssaison zurückhaltend
23-04-18	MÄRKTE USA/Uneinheitlich - Goldman Sachs bremst Dow
23-04-18	MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten
23-03-09	Wall Street hard onderuit in aanloop naar banencijfer

1 day	+46.67%
1 week	+70.81%
Current month	+13.49%
1 month	+62.96%
3 months	+82.66%
6 months	+193.33%
Current year	-35.31%

1 month	0.26	0.52
Current year	0.15	0.79
1 year	0.15	0.97
3 years	0.15	70.5
5 years	0.15	2,081.25
10 years	0.15	13,882.3

Manager	Title	Age	Since
Alexandra MacLean CEO	Chief Executive Officer	59	2022-07-31
David Jin CEO	Chief Executive Officer	36	2022-03-30
Jaclyn Jaffe IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Lindsay Rosenwald CHM	Chairman	71	2015-02-08
Neil Herskowitz BRD	Director/Board Member	69	2015-07-31
Jay Kranzler CHM	Chairman	68	2023-03-06

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/2/26	FORTRESS BIOTECH, INC.	Free	Company	111,209	3.4934%
3/31/25	FORTRESS BIOTECH, INC.	Free	Company	33,724	1.6419%
12/31/24	FORTRESS BIOTECH, INC.	Other	Company	294,800	15.4214%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVENUE THERAPEUTICS, INC.	+46.67%	+70.81%	-24.14%	-99.38%	849K
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+73.26%	+109.90%	72.12B
ARGENX SE	+1.90%	+23.53%	+59.48%	+94.82%	65.85B
BIONTECH SE	+5.12%	+25.22%	+5.13%	-5.86%	29.28B
INSMED INCORPORATED	+0.55%	+1.64%	-4.63%	+480.92%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+54.92%	+25.77%	26.7B
GENMAB A/S	+0.47%	+6.12%	+37.01%	-15.31%	20.06B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+251.36%	+388.91%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+15.30%	+548.19%	16.4B
EXELIXIS, INC.	+0.73%	+5.54%	+39.99%	+151.77%	13.4B
Average	+5.79%	+7.53%	+50.77%	+167.97%	28.95B
Weighted average by Cap.	+0.74%	+9.48%	+58.02%	+157.86%

	2024	2025
Net sales	-	1.4 1.2 1.13 1.03 1.93 134.33 1.96 13.3 5.18 67.48 5.27 5.16 223.2
Net income	-11.65M -9.98M -9.34M -8.55M -16.04M -1.11B -16.26M -110M -43.03M -560M -43.75M -42.8M -1.85B	-2.91M -2.49M -2.33M -2.13M -4.01M -278M -4.06M -27.55M -10.74M -140M -10.92M -10.69M -462M
Net Debt	-2.59M -2.22M -2.08M -1.9M -3.57M -248M -3.62M -24.56M -9.58M -125M -9.74M -9.53M -412M	-2.86M -2.45M -2.29M -2.09M -3.93M -273M -3.98M -27.04M -10.54M -137M -10.72M -10.49M -454M